Bavarian Nordic Receives Positive CHMP Opinion for Including Mpox Real-world Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

July 26, 2024 Health Trends, Health Trends - USA

Bavarian Nordic A/S

COPENHAGEN, Denmark, July 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a type II variation for IMVANEX^® (MVA-BN) smallpox and…

Source link

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.

Bavarian Nordic Receives Positive CHMP Opinion for Including Mpox Real-world Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

Recent Posts

Recent Comments